From the Journals

Opioids prescribed for diabetic neuropathy pain, against advice


 

Dr. McCoy offers clinical pearls for treating pain in DPN

Clinically, Dr. McCoy said that she individualizes treatment for painful DPN.

“I tend to use duloxetine if the patient also has a mood disorder including depression or anxiety, because it can also help with that. Gabapentin can also be helpful for radiculopathy or for chronic low-back pain. It can even help with degenerative joint disease like arthritis of the knees. So, you maximize benefit if you use one drug to treat multiple things.”

All three recommended medications are generic now, although pregabalin still tends to be more expensive, she noted. Gabapentin can cause drowsiness, which makes it ideal for a patient with insomnia but much less so for a long-haul truck driver. Duloxetine doesn’t cause sleepiness. Pregabalin can, but less so than gabapentin.

“I think that’s why it’s so important to talk to your patient and ask how the neuropathy is affecting them. What other comorbidities do they have? What is their life like? I think you have to figure out what drug works for each individual person.”

Importantly, she advised, if one of the three doesn’t work, stop it and try another. “It doesn’t mean that none of these meds work. All three should be tried to see if they give relief.”

Nonpharmacologic measures such as cognitive behavioral therapy, acupuncture, or physical therapy may help some patients as well.

Supplements such as vitamin B12 – which can also help with metformin-induced B12 deficiency – or alpha-lipoic acid may also be worth a try as long as the patient is made aware of potential risks, she noted.

Dr. McCoy hopes to repeat this study using national data. “I don’t think this is isolated to Mayo ... I think it affects all practices,” she said.

Since the study, “we [Mayo Clinic] have implemented practice changes to limit use of opioids for chronic pain ... so I hope it’s getting better. It’s important to be aware of our patterns in prescribing.”

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. McCoy reported receiving grants from the AARP Quality Measure Innovation program through a collaboration with OptumLabs and the Mayo Clinic’s Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Daily Recap: Lifestyle vs. genes in breast cancer showdown; Big pharma sues over insulin affordability law
MDedge Neurology
Good for profits, good for patients: A new form of medical visits
MDedge Neurology
Does metformin reduce risk for death in COVID-19?
MDedge Neurology
Vascular dementia risk particularly high in type 2 diabetes
MDedge Neurology
Smart health devices – promises and pitfalls
MDedge Neurology
Geriatric patients: My three rules for them
MDedge Neurology
Diabetic neuropathic pain linked to brain bioenergic anomalies
MDedge Neurology
COVID-19 antibody response not reduced with diabetes
MDedge Neurology
Diabetic retinopathy may predict greater risk of COVID-19 severity
MDedge Neurology
Prioritize COVID-19 vaccination in both types of diabetes, say docs
MDedge Neurology